{
  "abstract": "In recent years, the epidemiology of infective endocarditis (IE) has undergone a profound shift: intravenous drug use is no longer a marginal risk factor but a central driver of disease burden in many high-income countries. Among people who inject drugs (PWID), IE now accounts for an increasingly large proportion of cardiovascular-infectious admissions and presents with distinctive patterns of younger age, minimal structural heart disease, predominance of Staphylococcus aureus, right-sided valve involvement and frequent septic pulmonary complications.1",
  "authors": [
    {
      "affiliations": [
        "Cardiology, CHU La Timone, Aix-Marseille University, Marseille, France"
      ],
      "name": "Mary Philip"
    },
    {
      "affiliations": [
        "CEReSS-Health Service Research and Quality of Life Center, Aix-Marseille University, Marseille, France"
      ],
      "name": "Theo Korchia"
    },
    {
      "affiliations": [
        "Cardiology, CHU La Timone, Aix-Marseille University, Marseille, France"
      ],
      "name": "Gilbert Habib"
    }
  ],
  "title": "Fixing the heart but losing the patient: the moral architecture of drug use-associated endocarditis",
  "uid": "a53331c3-a187-5e49-95ab-ddf5de823f39"
}